Starting or Strengthening a Drug Bulletin - A Practical Manual
(2005; 165 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentHow the manual was produced
View the documentAbout ISDB
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Rational use of medicines
Open this folder and view contents3. What are drug bulletins?
Open this folder and view contents4. Defining aims, target and type of bulletin
Open this folder and view contents5. Planning resources
Open this folder and view contents6. Planning bulletin production: schedules and timing
Open this folder and view contents7. The editorial process
Open this folder and view contents8. Reviewing a new drug: is it a therapeutic advance?
Open this folder and view contentsAnnexe to Chapter 8: Evaluating harm
Close this folder9. Design and production
View the document9.1 Elements of good design
View the document9.2 Creating the design
View the document9.3 Using images
View the document9.4 The production process
View the document9.5 Developing a house style
View the document9.6 Ensuring accuracy - proof reading
View the document9.7 Printing
View the document9.8 Electronic publishing
View the document9.9 Further reading
Open this folder and view contents10. Dissemination
Open this folder and view contents11. Organizational and legal issues
Open this folder and view contents12. Evaluating quality and usefulness
Open this folder and view contents13. Partnership and collaboration
Open this folder and view contents14. Keeping records and creating a memory
Open this folder and view contentsAppendix: Electronic sources of information

9.5 Developing a house style

Permanent features of the layout, such as the name of the bulletin, will already have been defined in the design of the bulletin. But style issues, such as grammar, spelling and punctuation must also be dealt with consistently in each new issue. For example, what name do you use to describe a new class of non-steroidal anti-inflammatory drugs: COX-2 inhibitors or coxibs?; do you always write out the name of an institution such as the European Medicines Agency, or is the acronym EMEA alone sufficient? Do you call clinical trials by their acronyms (e.g. VIGOR) and how do you include them in the index so that they can be retrieved easily? (See Box 9.1). The way a bulletin represents certain things needs to be consistent between the articles in an issue and between issues. To achieve this consistency, it is good practice to have a house-style guide in the form of a sheet or a booklet containing style ‘rules’ and to incorporate in it all new decisions about style issues when they arise. It is a good idea for a new bulletin to adopt an established bulletin’s style guide while it develops its own (you could do this by contacting the editor of an ISDB member bulletin via Editors will need to refer to the house style during the editorial process, and it can also be used when the final checks are made during the production process.

Box 9.1 Examples of rules in a house-style guide

• Use of abbreviations, e.g. RCT, NSAID. (In general, try to avoid these).

• Drug names, e.g. beta-blockers or ß-blockers; adrenoceptors or adrenoreceptors; whether to use the generic name alone, or together with the trade name(s), whether to include the pharmaceutical company’s name.

• Drug doses, e.g. whether to write units in full or abbreviated, e.g. micrograms or mg.

• Use of italics (e.g. for genus and species names for bacteria and fungi).

• Numbers: when to write out in full.

• How to cite references.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017